TNX-1830 / Tonix, University of Alberta - LARVOL DELTA

Tonix Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Highlights (GlobeNewswire, Tonix Pharmaceuticals Holding Corp.) - "Research and Development....TNX-1800, TNX-1810, TNX-1820 and TNX-1830 are in the pre-clinical, pre-Investigational New Drug (IND) application stage of development. The company expects preliminary data from animal experiments with TNX-1800 in the fourth quarter of 2020, but the COVID-19 pandemic may lead to a delay in this timeline."

IND • Preclinical • CNS Disorders • Infectious Disease • Inflammation • Musculoskeletal Diseases • Novel Coronavirus Disease

Tonix Pharmaceuticals Enters into Research Collaboration and Exclusive License Agreement with University of Alberta to Develop Novel Horsepox-Based Vaccines, TNX-1810, TNX-1820 and TNX-1830, for the Prevention of COVID-19 (GlobeNewswire, Tonix Pharmaceuticals Holding Corp.) - "Tonix Pharmaceuticals Holding Corp....announced today a new research collaboration and exclusive licensing agreement for three new vaccines for the prevention of COVID-19....The new collaboration will develop three new potential vaccines to protect against COVID-19 based on the horsepox vector platform, but designed to express different SARS-CoV-2 antigens than TNX-1800, which is designed to express SARS-CoV-2 Spike protein....'We are excited to expand our pipeline and look forward to developing three additional potential vaccines, TNX-1810, TNX-1820 and TNX-1830 to protect against COVID-19'....Tonix has been granted an exclusive license from the University of Alberta for technology and patents related to TNX-1810, TNX-1820 and TNX-1830."

Licensing / partnership • New molecule • Infectious Disease • Novel Coronavirus Disease